Wall Street had a little less heartburn on Tuesday after the producer price index (PPI)—aka wholesale inflation—came in cooler than expected, sparking a 221-point rally in the Dow. That’s a 0.5% pop for the 30-stock index, while the S&P 500 eked out a modest 0.1% gain. The Nasdaq? Not so much. The tech-heavy index got dragged down 0.2% because Big Tech decided to once again ruin everyone's day.

In short, the reason for the somewhat green day is that the PPI rose just 0.2% in December, compared to Wall Street’s 0.4% estimate. Core PPI (because apparently eating and gas aren’t important) came in flat. Translation: inflation at the wholesale level is simmering down, and traders are now clutching their pearls over Wednesday’s CPI report.

The market’s been on pins and needles waiting for signs that the Fed’s war on inflation is actually working. So Tuesday’s PPI numbers were like a Xanax for Wall Street’s anxiety—less inflation pressure could mean the Fed chills out on its rate hikes, but it also means no necessity on cutting rates either. Meaning it’s a double-edged sword that the market is still trying to figure out overall. 

Meanwhile, individual stocks were throwing their own little parties—or funerals. Eli Lilly dropped faster than pants at a Weight Watchers reunion, slipping more than 7% after admitting it can’t keep up with demand for its weight-loss and diabetes drugs. Boeing slipped 2% because its 2024 airplane deliveries are looking about as reliable as a Spirit flight. 

On the upside, Applied Digital jumped 6% after Macquarie agreed to throw $5 billion at its AI data centers. In addition, Hesai, a Chinese auto supplier, saw an 8% bump after Goldman Sachs upgraded it to “buy,” while Bank of America was busy spreading double upgrades on Celanese like it was an STD at Coachella.  

But the real “get rekt” award goes to Signet Jewelers, which sank a brutal 26% after admitting holiday shoppers were too busy buying essentials like eggs and rent to splurge at Kay or Zales. Condolences to all those special ladies out there. 

In the end, the Dow’s 221-point gain may have been the headline Tuesday, but all eyes are now on Wall Street’s money shot: Wednesday’s CPI report. If inflation keeps cooling, we should make it through the week without getting financially violated—and if not, well then buckle up buttercup because it’s going to be one heck of a sh*t show. 

If you read all of this, congrats for having a 10 second attention span (better than me). As always, here’s our heatmap for today.

Wall Street DESTROYS Retail Stocks After Posting Better than Expected Numbers—Wait, What?!

Retailers rolled out their holiday sales updates this week, and if you’re looking for Wall Street’s reaction, it’s somewhere between “meh” and “McKayla is not impressed”. Despite a handful of big names like Lululemon, Abercrombie & Fitch, and American Eagle raising their guidance for the quarter, their stocks still got tossed into the red. Because as it turns out, exceeding expectations can still turn into a swift kick in the “valuation”. 

Take Lululemon, for instance. The athleisure juggernaut upped its sales and profit guidance, with CFO Meghan Frank patting herself on the back for a solid holiday season. But apparently, the market expected more than a 0.3 percentage point gross margin boost. Shares scraped out a tiny gain before the reality of Wall Street’s apathy set in. Simply put, this isn’t 2020 anymore, and no one’s paying Peloton-era premiums for stretchy pants, no matter how buttery soft they might be.

Additionally, Abercrombie & Fitch, couldn’t quite recapture its post pandemic mind-bending growth. Sure, it raised its holiday-quarter growth forecast from “decent” to “slightly better than decent,” but when you’re lapping last year’s...

Read The Full Story HERE

Mystery Pharma Unleashes "Cancer Killer" Drug?! Share Price Explodes 300%...

Well Phio Pharmaceuticals just gave short sellers the kind of day that makes them consider doing OnlyFans instead. In short, Phio went full diamond hands yesterday, surging 300% after the company dropped some seriously bullish Phase 1b trial results for its experimental cancer treatment, PH-762.

Interesting, more details please…

See, Phio’s headline-grabbing cancer drug, PH-762, is designed to turn the immune system into a tumor-seeking missile—and as expected, the company reported that patients in it’s Phase 1b trial saw some game-changing results, including: Two patients with cutaneous squamous cell carcinoma achieved a complete response (a.k.a., 100% tumor clearance). 1 patient clocked a partial response with 90% tumor clearance and another patient maintained stable disease without progressions. But the bigly part about it all? Is that there was zero dose-limiting toxicities or major side effects of the trial. 

Meaning, Phio Pharmaceuticals may actually be onto something. Naturally, acting Chief Medical Officer Mary Spellman basically said as much, adding they’re excited to push into higher doses. Translation: Let’s see how far we can turn this up without breaking the dial. Now with that that said, if you’re rolling your eyes thinking, “Great, another pump-and-dump biotech story,” I’d think twice. Simply put, PH-762 isn’t just some random Hail Mary drug—it’s powered by...

Read The Full Story HERE

CEO Buys $8 MILLION Near 52-Week Low...

Our "Insider Trade Tracker" recently flagged John F. Barry, CEO of Prospect Capital Corp, splurging $8.58 MILLION to scoop up 2 million shares of his own company’s stock at $4.29 per share. With PSEC trading near its 52-week low, Barry’s wallet says he’s betting big on the company’s 12.6% dividend yield and 21-year track record of payouts. Moves like this are why our tool is your ticket to tracking where the smart money flows… in real time.
Oh, and FYI, we recently ranked #23 for free News Apps, ahead of Bloomberg and The Washington Post.  Curious to see what other power plays we’re tracking? Become a Stocks.News premium member today… or just keep enjoying our free content. No pressure. 

Here's Everything You'll Get As A Stocks.News Premium Member

Front-Row Seat to Proprietary Stocks.News Trade Alerts

No more second-guessing or relying on stale information. Every week, you’ll receive real-time alerts that uncover the most explosive market opportunities before they make headlines. These alerts are your direct line to where the most explosive short squeezes are likely forming. Whether a stock is experiencing massive short-interest, outrageous borrowing fees, or potent dilution you’ll know about it BEFORE the fireworks begin. 

Private Access to the Stocks.News Dashboard

Imagine having a personalized command center for your trading. Inside your exclusive member dashboard, you’ll find our point system to leverage at your disposal. These points will help you utilize more opportunities when it comes to taking the guesswork out of your research—whether it’s cutting through the noise or highlighting the trades with the highest potential. 

Fresh Morningstar Reports Daily

Get access to daily updates from Morningstar, one of the most trusted names in stock research. These reports deliver cutting-edge stock ratings and insights, giving you the confidence to make informed decisions about where to place your bets accordingly—regardless if you’re a day trader or buy and hold investor. 

Proprietary Insider Trade Scanner

Ever wonder what corporate insiders are doing with their own cash? With our Insider Trade Scanner, you’ll see exactly where CEOs, executives, and board members are placing their bets. These trades are often the strongest signals of what’s coming next—and now, you can follow their lead.

Proprietary Congressional Trade Scanner

Forget the headlines—our Congressional Trade Scanner gives you a direct view into the investments being made by the most well-connected people in the country. From lawmakers to policymakers, you’ll know what they’re buying and selling before the news breaks.

Stocks.News High/Low PE Stock Stress Test

Finding undervalued stocks with explosive potential has never been more effective. Our High/Low PE Stock Stress Test cuts through market clutter to identify stocks that are either extremely undervalued to take advantage of or far too overvalued to avoid. Consider this tool as  your shortcut to spotting opportunities that others are overlooking or overhyping. 

Market Breadth and Market Sentiment Gauge

Short-term vision is great, but the bigger picture is what really drives the market forward. Our proprietary sentiment tools give you a clear view of market strength and direction. With real-time sentiment analysis and breadth indicators, you’ll always have your finger on the market’s pulse—helping you stay ahead of major moves.

Stocks.News Technical Analysis Screener

For those who love technicals, this screener is your new best friend. It simplifies complex chart analysis into actionable insights, helping you identify key setups in seconds. Whether you’re a seasoned chartist or just starting out, this screener not only gives you a decisive edge over the competition—but it reveals exactly what the price action of a stock is really saying compared to its fundamentals.  

Here’s the deal…

If you’ve ever felt like the market was stacked against you, this is your chance to flip the script.

Stocks.News Premium strives to give you the same level of information, tools, and market insights that institutional traders and Wall Street use every day.

The only difference? Now, they’re in your hands.

Of course, we can’t promise you’ll always catch a winning opportunity. No one can. But we can say this:

When you start deciphering the market into its purest form…

Everything about the way you trade and invest is set to change.

The best part?

You can get access to everything above for just $20 a month!

I know, absolutely ludicrious, amirite?

Click here to claim your premium Stocks.News membership today!

Robinhood’s in Hot Water for Covering Up Short Sales And Reporting Corrupt Trade Data

Remember that kid from high school? The good-looking one with straight A’s, full-ride scholarships to Ivy League schools, and a future so perfect it made your mom ask why you couldn’t be more like them? Yeah, the one who also couldn’t stop dabbling in, let’s say, extracurricular substances (aka crack). That’s Robinhood… the fintech cool kid that became famous during the pandemic but just can’t seem to stay out of trouble.

Back in 2020, Robinhood was “HIM” (as the teenagers say). People were slinging stimulus checks on Tesla shares and GameStop call options like they were on a Carnival cruise with free drinks. But then came the freeze. During the GameStop meme stock frenzy, Robinhood paused trading, blaming “market stability.” But we all know what really happened: They bent the knee to their Wall Street sugar daddies who needed to exit their positions without blowing up. Public trust took a nosedive, and so did Robinhood’s stock post-IPO (remember that Dave Portnoy/Vlad interview?).

Fast forward to 2025, and Robinhood’s been on a tear. The stock is up 262% year-to-date, making it Yahoo Finance’s “comeback stock” of the year. Vlad Tenev is all smiles on Zoom interviews, basking in accolades and dreaming about crypto-friendly deregulation under a possible second Trump administration. But just like that high school kid who shows up to the 10 year reunion with a new Tesla but still “borrows” cash from their grandma and has an ankle monitor, Robinhood has some...

Read The Full Story HERE

We’re gonna talk about a topic that’s barely getting any attention: the chip sector (wink, wink) . It’s the lifeblood of everything from your overpriced smartphone to the AI bots writing cringy LinkedIn posts and spamming my inbox with “Let’s connect!” messages. But right now, it feels like someone spilled their piping hot latte on the motherboard. Nvidia is down 13% in the last five days, Taiwan Semiconductor is off 8%, and YouTube’s top finance video is shouting about a semiconductor apocalypse that would make 1929 look like a walk in the park.

Sure, there’s pessimism swirling around the sector. High interest rates staying around longer, Trump tariff concerns, and the realization that not everyone needs a $3,000 AI GPU to run "Fortnite" have put the sector on edge. But in the middle of this firestorm, one name is quietly sitting in the coals, primed for a comeback: ASML Holding. I’m sure you’ve barely heard of ASML. That’s because Nvidia and TSMC hog the stage, like the headliners at Coachella. But ASML is the guy in the background running the soundboard… without it, the whole concert falls apart.

Alright, let me grab my nerd glasses and explain why ASML matters (don’t worry, I promise it’s worth it). They’re the geniuses behind extreme ultraviolet (EUV) lithography machines… basically, the unsung heroes of advanced chip production. These machines are engineering marvels, using lasers to fire at molten tin droplets 50,000 times per second to etch the intricate designs that make chips work. Each one comes with a price tag of $220 million, and their next-gen models crank that up to $380 million. It’s safe to say these are some of the most advanced...

Read The Full Story HERE

Stocks.News holds positions in Tesla and Robinhood as mentioned in the article.